Abstract
The US orthopedic biomaterial market was valued at almost $2 billion in 2006.
This market is comprised of growth factor technologies, bone graft
substitutes, hyaluronic acid viscosupplementation, machined bone interbody
devices, osteoarticular allografts & autologous chondrocyte implantation,
platelet concentration systems, and orthopedic stem cell products.
View Cart
